RecruitingNCT07017699

A Study to Assess Deucravacitinib Safety in Pregnancy

The Deucravacitinib Pregnancy Exposure Study: A Prospective Observational Study of Deucravacitinib Safety in Pregnancy

Sponsor

Bristol-Myers Squibb

Enrollment

900 participants

Start Date

Mar 21, 2025

Study Type

OBSERVATIONAL

Conditions

Psoriasis (PsO)

Summary

The purpose of this study is to assess pregnancy and infant outcomes among pregnant participants enrolled in an established North American pregnancy registry (Organization of Teratology Information Specialists \[OTIS\]) who were exposed to deucravacitinib.

Eligibility

Sex: FEMALE

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deucravacitinib and a drug called Other systemic treatments for PsO for people with psoriasis (pso). The study is currently recruiting participants at 1 location. People eligible for this study include women.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDeucravacitinib

According to product label

DRUGOther systemic treatments for PsO

According to product label

Locations(1)

University of California San Diego

La Jolla, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07017699

Related Trials

Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis

NCT074019921 location

Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada

NCT073707666 locations